Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CYTR's Cash to Debt is ranked higher than
96% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. CYTR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CYTR' s Cash to Debt Range Over the Past 10 Years
Min: 2.95  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
CYTR's Interest Coverage is ranked higher than
94% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CYTR' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: -1.89
M-Score: -0.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -53651.00
CYTR's Operating margin (%) is ranked lower than
98% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. CYTR: -53651.00 )
Ranked among companies with meaningful Operating margin (%) only.
CYTR' s Operating margin (%) Range Over the Past 10 Years
Min: -49606  Med: -8754.72 Max: -80.47
Current: -53651
-49606
-80.47
Net-margin (%) -49723.00
CYTR's Net-margin (%) is ranked lower than
98% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. CYTR: -49723.00 )
Ranked among companies with meaningful Net-margin (%) only.
CYTR' s Net-margin (%) Range Over the Past 10 Years
Min: -30118  Med: -3290.42 Max: 408
Current: -49723
-30118
408
ROE (%) -81.85
CYTR's ROE (%) is ranked lower than
77% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. CYTR: -81.85 )
Ranked among companies with meaningful ROE (%) only.
CYTR' s ROE (%) Range Over the Past 10 Years
Min: -342.91  Med: -86.58 Max: 1.39
Current: -81.85
-342.91
1.39
ROA (%) -62.84
CYTR's ROA (%) is ranked lower than
76% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CYTR: -62.84 )
Ranked among companies with meaningful ROA (%) only.
CYTR' s ROA (%) Range Over the Past 10 Years
Min: -201.4  Med: -46.69 Max: 1.13
Current: -62.84
-201.4
1.13
ROC (Joel Greenblatt) (%) -5730.72
CYTR's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. CYTR: -5730.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYTR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -12894.39  Med: -2407.93 Max: -723.27
Current: -5730.72
-12894.39
-723.27
Revenue Growth (3Y)(%) -100.00
CYTR's Revenue Growth (3Y)(%) is ranked lower than
93% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. CYTR: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYTR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -11.30 Max: 188.4
Current: -100
-100
188.4
EBITDA Growth (3Y)(%) -10.30
CYTR's EBITDA Growth (3Y)(%) is ranked lower than
60% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. CYTR: -10.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYTR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.3  Med: -10.50 Max: 144.7
Current: -10.3
-67.3
144.7
EPS Growth (3Y)(%) -11.70
CYTR's EPS Growth (3Y)(%) is ranked lower than
58% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CYTR: -11.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYTR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.3  Med: -15.00 Max: 94.8
Current: -11.7
-55.3
94.8
» CYTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CYTR Guru Trades in

CYTR Guru Trades in

CYTR Guru Trades in

Q2 2014

CYTR Guru Trades in Q2 2014

George Soros Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.85
CYTR's P/B is ranked higher than
68% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. CYTR: 1.85 )
Ranked among companies with meaningful P/B only.
CYTR' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 3.62 Max: 64.65
Current: 1.85
1.03
64.65
P/S 1022.69
CYTR's P/S is ranked lower than
99.99% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. CYTR: 1022.69 )
Ranked among companies with meaningful P/S only.
CYTR' s P/S Range Over the Past 10 Years
Min: 0  Med: 231.00 Max: 1092.02
Current: 1022.69
0
1092.02
Current Ratio 5.59
CYTR's Current Ratio is ranked higher than
56% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. CYTR: 5.59 )
Ranked among companies with meaningful Current Ratio only.
CYTR' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 4.56 Max: 30
Current: 5.59
1.04
30
Quick Ratio 5.59
CYTR's Quick Ratio is ranked higher than
57% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. CYTR: 5.59 )
Ranked among companies with meaningful Quick Ratio only.
CYTR' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 4.56 Max: 30
Current: 5.59
1.04
30
Days Sales Outstanding 6.00
CYTR's Days Sales Outstanding is ranked higher than
92% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. CYTR: 6.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.94  Med: 235.06 Max: 7752.6
Current: 6
4.94
7752.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.03
CYTR's Price/Net Cash is ranked higher than
83% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. CYTR: 2.03 )
Ranked among companies with meaningful Price/Net Cash only.
CYTR' s Price/Net Cash Range Over the Past 10 Years
Min: 0.55  Med: 5.47 Max: 458
Current: 2.03
0.55
458
Price/Net Current Asset Value 1.95
CYTR's Price/Net Current Asset Value is ranked higher than
84% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. CYTR: 1.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYTR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.43  Med: 4.14 Max: 108.89
Current: 1.95
0.43
108.89
Price/Tangible Book 1.86
CYTR's Price/Tangible Book is ranked higher than
80% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CYTR: 1.86 )
Ranked among companies with meaningful Price/Tangible Book only.
CYTR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.34  Med: 3.16 Max: 65.43
Current: 1.86
0.34
65.43
Earnings Yield (Greenblatt) (%) -114.49
CYTR's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CYTR: -114.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYTR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -185.7  Med: 2011.20 Max: 3114.3
Current: -114.49
-185.7
3114.3

More Statistics

Revenue(Mil) $1
EPS $ -0.87
Beta2.63
Short Percentage of Float17.26%
52-Week Range $1.55 - 5.42
Shares Outstanding(Mil)66.48

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 22 84
EPS($) -0.85 -1.01 -1.21 -0.79
EPS without NRI($) -0.85 -1.01 -1.21 -0.79

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CX5N.Germany,
CytRx Corp is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. Tamibarotene is an orally available, synthetic retinoid, rationally designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the current first-line treatment for acute promyelocytic leukemia, or APL. Bafetinib (formerly INNO-406) is an orally bioavailable, rationally-designed inhibitor of several Src kinases developed by the Japanese pharmaceutical company, Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia. The Company do not have manufacture supplies of aldoxorubicin or any of our other product candidates accordingly it is dependent upon third-party manufactures, or potential future strategic alliance partners, to manufacture these supplies. The Company has manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. The Company's plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.
» More Articles for CYTR

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
CytRx to Present at the 18th Annual BIO CEO & Investor Conference Feb 01 2016
CytRx to Present at the 18th Annual BIO CEO & Investor Conference Feb 01 2016
New Strong Buy Stocks for January 14th Jan 14 2016
CYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 11 2016
CytRx Corporation Appoints Olivia Ware as Chief Commercial Officer Jan 11 2016
CytRx Corporation Appoints Olivia Ware as Chief Commercial Officer Jan 11 2016
CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers Jan 07 2016
Coverage initiated on CytRx by Jefferies Jan 07 2016
CYTRX CORP Files SEC form 8-K, Other Events Jan 06 2016
CytRx Announces Settlement of California Stockholder Derivative Lawsuit Jan 05 2016
CytRx Announces Settlement of California Stockholder Derivative Lawsuit Jan 05 2016
The Road Ahead - New Reports on AppFolio, CytRx, USA Truck and Egalet Dec 17 2015
CYTRX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 10 2015
CytRx Announces Settlement of the Consolidated Securities Class Action Lawsuit Dec 10 2015
CytRx Announces Settlement of the Consolidated Securities Class Action Lawsuit Dec 10 2015
CYTRX CORP Financials Dec 08 2015
CytRx Nominates Next Clinical Drug Candidate DK049 Dec 07 2015
CytRx Announces Participation at the 26th Annual Oppenheimer Healthcare Conference Dec 03 2015
CytRx Corporation (CYTR): Hedge Funds Are Snapping Up Dec 02 2015
CytRx Announces the Completion of Enrollment in Pivotal Global Phase 3 Trial Ahead of Schedule Dec 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK